How many stocks are there of BB Biotech?
The current number of stocks of BB Biotech is 54.85 M undefined.
BB Biotech Stocks 2024
BB Biotech Stocks
54.85 M
Ticker
BION.SW
ISIN
CH0038389992
WKN
A0NFN3
In 2024, BB Biotech had 54.85 M outstanding stocks, a 0% change from the 54.85 M stocks in the previous year.
The BB Biotech Stocks history
| YEAR | NUMBER OF STOCKS (undefined CHF) |
|---|---|
| 2026e | 54.85 |
| 2025e | 54.85 |
| 2024e | 54.85 |
| 2023 | 54.85 |
| 2022 | 55.01 |
| 2021 | 55.36 |
| 2020 | 55.39 |
| 2019 | 55.4 |
| 2018 | 55.4 |
| 2017 | 55.35 |
| 2016 | 55.27 |
| 2015 | 55.87 |
| 2014 | 56.65 |
| 2013 | 57 |
| 2012 | 58.6 |
| 2011 | 65.8 |
| 2010 | 79 |
| 2009 | 82.7 |
| 2008 | 88.5 |
| 2007 | 106.4 |
| 2006 | 119.1 |
| 2005 | 120.4 |
| 2004 | 125.5 |
BB Biotech shares outstanding CH0038389992 · A0NFN3
The number of shares was BB Biotech in 2023 — This indicates how many shares 54.846 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue BB Biotech earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates BB Biotech's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of BB Biotech’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BB Biotech's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 125.5 M Aktien |
| 2005 | 120.4 M Aktien |
| 2006 | 119.1 M Aktien |
| 2007 | 106.4 M Aktien |
| 2008 | 88.5 M Aktien |
| 2009 | 82.7 M Aktien |
| 2010 | 79 M Aktien |
| 2011 | 65.8 M Aktien |
| 2012 | 58.6 M Aktien |
| 2013 | 57 M Aktien |
| 2014 | 56.65 M Aktien |
| 2015 | 55.87 M Aktien |
| 2016 | 55.27 M Aktien |
| 2017 | 55.35 M Aktien |
| 2018 | 55.4 M Aktien |
| 2019 | 55.4 M Aktien |
| 2020 | 55.39 M Aktien |
| 2021 | 55.36 M Aktien |
| 2022 | 55.01 M Aktien |
| 2023 | 54.85 M Aktien |
| 2024e | 54.85 M Aktien |
| 2025e | 54.85 M Aktien |
| 2026e | 54.85 M Aktien |
BB Biotech Aktienanalyse
What does BB Biotech do?
BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating BB Biotech's Shares Outstanding
BB Biotech's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in BB Biotech’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding BB Biotech’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in BB Biotech’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about BB Biotech stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of BB Biotech are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of BB Biotech evolved in recent years?
The number of shares of BB Biotech has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. BB Biotech as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of BB Biotech?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does BB Biotech pay?
Over the past 12 months, BB Biotech paid a dividend of 2.85 CHF . This corresponds to a dividend yield of about 7.67 %. For the coming 12 months, BB Biotech is expected to pay a dividend of 2.57 CHF.
What is the dividend yield of BB Biotech?
The current dividend yield of BB Biotech is 7.67 %.
When does BB Biotech pay dividends?
BB Biotech pays a quarterly dividend. This is distributed in the months of April, April, April, April.
How secure is the dividend of BB Biotech?
BB Biotech paid dividends every year for the past 14 years.
What is the dividend of BB Biotech?
For the upcoming 12 months, dividends amounting to 2.57 CHF are expected. This corresponds to a dividend yield of 6.91 %.
In which sector is BB Biotech located?
BB Biotech is assigned to the '-' sector.
Wann musste ich die Aktien von BB Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BB Biotech from 3/27/2024 amounting to 2 CHF, you needed to have the stock in your portfolio before the ex-date on 3/25/2024.
When did BB Biotech pay the last dividend?
The last dividend was paid out on 3/27/2024.
What was the dividend of BB Biotech in the year 2023?
In the year 2023, BB Biotech distributed 3.85 CHF as dividends.
In which currency does BB Biotech pay out the dividend?
The dividends of BB Biotech are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The BB Biotech stock can be added to a savings plan with the following providers: ING
Andere Kennzahlen von BB Biotech
Our stock analysis for BB Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.